


Electronic Filing System (EFS) Data
Electronic Patent Application Submission
USPTO Use Only

EFS ID: 11170
Application ID: 09681408
Title of Invention: Methods and Systems for
Implementing a Profitability
Model
First Named Inventor: Anthony Casciano
Domestic/Foreign Application: Domestic Application
Filing Date: null
Effective Receipt Date: 2001-03-30
Submission Type: Utility Patent Filing
Filing Type: new-utility
Confirmation Number: 0
Attorney Docket Number: 17243-00039
Digital Certificate Holder: cn=Robert E. Slenker, ou=Registered Attorneys, ou=Patent and
Trademark Office, ou=Department of Commerce, o=U.S.
Government, c=US
Certificate Message Digest: rlrWe4EyKIEO9+NxISy/1w==
Total Fees Authorized: \$1714.0
Payment Category: DA - Deposit Account
Deposit Account Number: 12384
Deposit Account Name: Robert E. Slenker



TRANSMITTAL FORM



Electronic Version
1.0.2

Stylesheet Version: 1.0

Attorney Docket
Number:

17243-
00039

Methods and Systems for Implementing a Profitability Model

First Named Inventor: Mr. Anthony G. Casciano

SUBMITTED BY

Name:	Mr. Robert E. Slenker
Registration Number:	45112
Electronic Signature Mark: Robert E. Slenker	Date Signed: 20010330

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

bibd-transmittal	1724393apds.xml
fee-transmittal	1724393fee.xml
specification	APP.xml

Comments:

Case	Age	Sex	Site	Pathologic	Survival
1	65	M	Rectum	Adenocarcinoma	10 mo
2	68	M	Rectum	Adenocarcinoma	12 mo
3	70	M	Rectum	Adenocarcinoma	14 mo
4	72	M	Rectum	Adenocarcinoma	16 mo
5	74	M	Rectum	Adenocarcinoma	18 mo
6	76	M	Rectum	Adenocarcinoma	20 mo
7	78	M	Rectum	Adenocarcinoma	22 mo
8	80	M	Rectum	Adenocarcinoma	24 mo
9	82	M	Rectum	Adenocarcinoma	26 mo
10	84	M	Rectum	Adenocarcinoma	28 mo
11	86	M	Rectum	Adenocarcinoma	30 mo
12	88	M	Rectum	Adenocarcinoma	32 mo
13	90	M	Rectum	Adenocarcinoma	34 mo
14	92	M	Rectum	Adenocarcinoma	36 mo
15	94	M	Rectum	Adenocarcinoma	38 mo
16	96	M	Rectum	Adenocarcinoma	40 mo
17	98	M	Rectum	Adenocarcinoma	42 mo
18	100	M	Rectum	Adenocarcinoma	44 mo
19	102	M	Rectum	Adenocarcinoma	46 mo
20	104	M	Rectum	Adenocarcinoma	48 mo
21	106	M	Rectum	Adenocarcinoma	50 mo
22	108	M	Rectum	Adenocarcinoma	52 mo
23	110	M	Rectum	Adenocarcinoma	54 mo
24	112	M	Rectum	Adenocarcinoma	56 mo
25	114	M	Rectum	Adenocarcinoma	58 mo
26	116	M	Rectum	Adenocarcinoma	60 mo
27	118	M	Rectum	Adenocarcinoma	62 mo
28	120	M	Rectum	Adenocarcinoma	64 mo
29	122	M	Rectum	Adenocarcinoma	66 mo
30	124	M	Rectum	Adenocarcinoma	68 mo
31	126	M	Rectum	Adenocarcinoma	70 mo
32	128	M	Rectum	Adenocarcinoma	72 mo
33	130	M	Rectum	Adenocarcinoma	74 mo
34	132	M	Rectum	Adenocarcinoma	76 mo
35	134	M	Rectum	Adenocarcinoma	78 mo
36	136	M	Rectum	Adenocarcinoma	80 mo
37	138	M	Rectum	Adenocarcinoma	82 mo
38	140	M	Rectum	Adenocarcinoma	84 mo
39	142	M	Rectum	Adenocarcinoma	86 mo
40	144	M	Rectum	Adenocarcinoma	88 mo
41	146	M	Rectum	Adenocarcinoma	90 mo
42	148	M	Rectum	Adenocarcinoma	92 mo
43	150	M	Rectum	Adenocarcinoma	94 mo
44	152	M	Rectum	Adenocarcinoma	96 mo
45	154	M	Rectum	Adenocarcinoma	98 mo
46	156	M	Rectum	Adenocarcinoma	100 mo
47	158	M	Rectum	Adenocarcinoma	102 mo
48	160	M	Rectum	Adenocarcinoma	104 mo
49	162	M	Rectum	Adenocarcinoma	106 mo
50	164	M	Rectum	Adenocarcinoma	108 mo
51	166	M	Rectum	Adenocarcinoma	110 mo
52	168	M	Rectum	Adenocarcinoma	112 mo
53	170	M	Rectum	Adenocarcinoma	114 mo
54	172	M	Rectum	Adenocarcinoma	116 mo
55	174	M	Rectum	Adenocarcinoma	118 mo
56	176	M	Rectum	Adenocarcinoma	120 mo
57	178	M	Rectum	Adenocarcinoma	122 mo
58	180	M	Rectum	Adenocarcinoma	124 mo
59	182	M	Rectum	Adenocarcinoma	126 mo
60	184	M	Rectum	Adenocarcinoma	128 mo
61	186	M	Rectum	Adenocarcinoma	130 mo
62	188	M	Rectum	Adenocarcinoma	132 mo
63	190	M	Rectum	Adenocarcinoma	134 mo
64	192	M	Rectum	Adenocarcinoma	136 mo
65	194	M	Rectum	Adenocarcinoma	138 mo
66	196	M	Rectum	Adenocarcinoma	140 mo
67	198	M	Rectum	Adenocarcinoma	142 mo
68	200	M	Rectum	Adenocarcinoma	144 mo
69	202				

FEE TRANSMITTAL

Electronic Version 1.0.4

Stylesheet Version: 1.0

Patent fees are subject to annual revisions on or about October 1st of each year.

Large Entity

TOTAL FEES AUTHORIZED: \$ 1714

The commissioner is hereby authorized to charge indicated processing and/or publication fees and credit any overpayments to:

Deposit Account Number: 01-2384



Deposit Account Name: Armstrong Teasdale LLP

Charge Any Additional Fee Required Under 37 C.F.R. Sections 1.16 and 1.17.

SUBMITTED BY

Authorized Name: Robert E. Slenker

Electronic Signature Mark: Robert E. Slenker

Date Signed: 20010330

BASIC FILING FEE

Fee Description	Fee Code	Fee Paid
Utility Filing Fee	101	\$ 710

Subtotal For Basic Filing Fee: \$ 710

EXTRA CLAIM FEES

	Fee Code	Fee	Extra Claims	Fee Paid
Total Claims: 58	103	\$ 18	38	\$ 684
Independent Claims: 7	102	\$ 80	4	\$ 320

Subtotal For Extra Claims Fees: \$ 1004